Condition: CD7 Positive R/R PTCL · Sponsor: Peking University People's Hospital
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed PTCL.
This description comes directly from the study's public registry record.
Xiaodong Mo, phd · 8610-88326002 · mxd453@163.com
Na Kuang · 86-18630160116 · kuangna@senlangbio.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07143929